Pharmafile Logo

07 Good Pharma

Better for patients, better for business

Pharma is a dirty word to some. Even to those with milder views, it’s an industry often painted with an unenviable public image. Negative portrayals of massive conglomerates that happily trade patient wellbeing for profits are too frequently projected upon the pharmaceutical sector from those outside of it. Indisputably, pharma companies are powered by profit, but so is any business. Revenue pays salaries and overheads. It’s the lifeblood of any company, big or small. Why then, does pharma get such a bad rep?

Because it matters. Because we are an ageing population terrified by the concept of growing old. Because we are more aware of our lifestyle choices, more informed about serious illness and more concerned about what it means to us. Healthcare is vital to protecting that most sacred of human commodities; our lives. It’s a big responsibility and so it’s perhaps natural that, as a wider society, we’re critical of those charged with looking after us.

So who should run pharma – shareholders or stakeholders? Both. At Havas Lynx we are passionate about improving patients’ lives and we know that the pharmaceutical companies we work with share this commitment. We believe that the key to long-term success is finding a balance between making money and making a difference. By combining moral and commercial drivers, companies can breed a long-term financial security that allows continued investment in life-changing innovations.

This content was provided by Havas Lynx

Documents for download:

Company Details

 Latest Content from  Havas Lynx 

Doctored Truths urges pharma to lead the fight against health misinformation

“Doctored Truths” exposes the escalating crisis of health misinformation and disinformation, which has been ranked the world’s top short-term risk to the world, for the second year in a row....

Havas Lynx Welcomes New Leadership Hires

Havas Lynx announces the appointment of Ayesha Walawalkar as Chief Strategy Officer, and Talin Apkarian as Havas Lynx Hudson Managing Director.

Havas to Open New Manchester Village at Circle Square

The global communications group will unite six agencies under one roof in a purpose-built, hybrid workspace at the heart of Manchester’s innovation district

Havas Lynx launches proprietary data product to drive meaningful change across pharma

Leading global healthcare communications agency, Havas Lynx , has launched its proprietary data platform, Point.1, to help pharmaceutical companies to gain a deeper understanding of healthcare professionals (HCPs) to drive...

Healing the Healers

Because if we do not heal the healers, who is going to heal us?

THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide

The campaign encourages people who use drugs to do something remarkable – save a life

Andi Goes – the children’s book that helps detect early signs of dyslexia

Havas Lynx Group have launched a children’s book aimed at raising awareness and detecting early signs of dyslexia. Helping to make sure that parents have the support they need whilst...

Neurofibromatosis: a condition that’s hard to say, but even harder to live with

The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).

Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond

Havas Health & You (HH&Y) have launched the details of a long-term global research project, Behind the Mask, a longitudinal, multi-armed study which focuses on documenting the ongoing evolution of...

Media Means Business

Creating meaningful media experiences in pharma